Progress in Personalizing Chemotherapy for Bladder Cancer

摘要: Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict response in this disease setting. A better understanding biology cancer has led developments molecular biomarkers that may help guide clinical decision making. These biomarkers, while promising, have not yet been validated prospective trials ready applications. As alkylating agents, platinum drugs kill cells mainly through induction DNA damage. microdosing approach being tested determine if chemoresistance can be identified by measuring platinum-induced damage using highly sensitive accelerator mass spectrometry technology. The hope these emerging strategies will pave road towards personalized therapy